

From: Maruna, Thomas
Sent: Thursday, March 10, 2016 10:28 AM
To: 'Angela.Azzara@cs Behring.com'; KevinDarryl.White@cs Behring.com
Subject: March 10. 2016 Information Request - BLA 125591.0 - Please Respond By March 18. 2016

Importance: High

CSL Behring Recombinant Facility AG
Attention: Mr. Kevin Darryl White
March 10, 2016
Sent by email

Dear Mr. White:

We are reviewing your May 29, 2015 biologics license application (BLA) for the following:

STN	Name of Biological Products
125591/0	Antihemophilic Factor (Recombinant), Single Chain

We have determined that the following information is necessary to continue review:

1. In the document "Summary report on the structural characterization of recombinant single-chain Factor VIII (rVIII-SingleChain)" in section 3.2.S.3.1-1, you included detailed structural characterization of the (b) (4) (b) (4) (b) (4) If available, please provide the (b) (4) (b) (4)

The review of this submission is on-going and issues may be added, expanded upon, or modified as we continue to review this submission.

Please submit your responses as an amendment to this file by March 18, 2016 referencing the date of this request.

The action due date for this file is May 28, 2016.

If you have any questions, please contact me.

Very Respectfully,

Thomas J. Maruna, MSc, MLS(ASCP), CPH
Lieutenant, U.S. Public Health Service
Senior Regulatory Management Officer
Food and Drug Administration
Center for Biologics Evaluation and Research
Office of Blood Research and Review

10903 New Hampshire Ave.
Silver Spring, MD 20993
thomas.maruna@fda.hhs.gov
O: (240) 402-8454
www.usphs.gov



"THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.